José Delgado (Yale) independently developed chronic depth-electrode implants in psychotic patients at almost exactly the same time as Heath — his 1952 paper narrowly pre-empted Heath's first human report (Blackwell, INHN case study). In 23 schizophrenic patients, septal stimulation produced alertness, increased verbal output and sometimes euphoria; and in a systematic study a narcoleptic patient was given a portable self-stimulator with automatic counters for 17 weeks — his highest rate was at a septal point, which he said made him feel "good… as if building up to a sexual orgasm," and which relieved his narcolepsy (Delgado, "Physical Control of the Mind" (1969)). Delgado's group later reported euphoria after septum stimulation in depressed patients (European Psychiatry tribute).
Carl Wilhelm Sem-Jacobsen (Mayo Clinic/Oslo) — depth stimulation in psychiatric and epileptic patients from the early 1950s (Mayo Clinic Proceedings, 1953), and by 1976 a report explicitly titled "Electrical stimulation and self-stimulation in man with chronic implanted electrodes," including cautions about interpretation and pitfalls (Sem-Jacobsen, 1976, Dietrichs, Neurology).
2. Why direct replication stopped
After the 1973 Senate scrutiny of Heath, tightening research-ethics rules, and the field's disgust at the B-19 episode, no one has ever run a formally approved, direct replication of human septal self-stimulation. Heath's work is now "only rarely used as reference material" (Wikipedia), a trajectory charted in retrospective accounts (The Lancet Neurology).
The paradigm migrated to animals: intracranial self-stimulation became a standard rodent procedure, but consolidated on the medial forebrain bundle/lateral hypothalamus rather than the septum (Negus & Miller, ICSS methodology review). Modern optogenetic ICSS extends the technique to identified circuits (optogenetic ICSS chapter, oICSS review), and the septal ICSS substrate has only recently been revisited in animals — still without a settled mechanism (bioRxiv, lateral septum).
3. What failed to replicate outright
The disease-level claims: Heath's taraxein hypothesis (that a blood protein from schizophrenics induces psychosis) drew wide attention in 1956 but replication attempts mostly failed, and psychiatry textbooks stopped endorsing it by the 1970s–80s (Wikipedia). Heath himself eventually concluded septal stimulation gave no permanent benefit in schizophrenia, despite early enthusiasm; ironically, his "septum" overlaps what we now call the nucleus accumbens, a genuine reward-circuit hub, so the anatomy outlived the theory (New Scientist).
The B-19 "conversion": nobody replicated it; the arousal was temporary and the patient's attractions did not change (Wikipedia).
4. Inadvertent modern replication: psychiatric DBS side effects (1999–2010s)
When DBS moved into psychiatry — Nuttin's 1999 anterior-capsule implants for OCD onward (Neurosurgery India review, citing Nuttin et al.), the VC/VS worldwide OCD experience (J Neurosurg Case Lessons), nucleus accumbens DBS for depression (Schlaepfer, Bewernick and colleagues) — clinicians repeatedly stumbled into Heath-like phenomena, now classified as adverse effects to be managed, not treatment:
Rapid responders showing disinhibition, gambling and hypomania-like recklessness at VC/VS stimulation (J Neurosurg Case Lessons, 2025).
5. Deliberate extension: stimulating Heath's "pleasure pathway" for depression
Heath had demarcated the medial forebrain bundle (MFB) and interpeduncular nucleus as human pleasure areas in 1972 (Heath, 1972). Fifty years later, Coenen's Freiburg group and Fenoy's Houston group built depression trials precisely on that tract: superolateral MFB DBS produced fast, sustained antidepressant effects in open series and a gateway trial — MADRS falling from ~29.6 to ~12.9 at 12 months (Coenen et al., 2019, Molecular Psychiatry 2021, Fenoy et al., cited in Translational Psychiatry, Molecular Psychiatry 2022, long-term). Intraoperative stimulation reportedly produces immediate mood lifts, though modern teams frame it as circuit modulation rather than "pleasure."
7. Interpretive extension: was Heath's "pleasure" pleasure?
Berridge and Kringelbach's influential synthesis concludes that "classic pleasure electrodes" (Heath's included) and mesolimbic dopamine may generate wanting without liking — compulsion and craving, not felt hedonic tone — with true "liking" confined to small hedonic hotspots (Berridge & Kringelbach, Neuron 2015). This reframes B-19's 1,500 presses and the modern hypomania cases as reward-seeking phenomena.
8. Current frontier
Closed-loop, responsive DBS of the ventral striatum (detecting obsession-related electrophysiology and stimulating only when needed) is now in first-in-human use for OCD — the direct technological descendant of Heath's implant-and-stimulate approach, minus the self-stimulation button (Nho et al., Neuron 2024).
Systematic intraoperative valence testing is being used to adjudicate target choice between VC/VS and BNST (Shofty et al., cited in J Neurosurg Case Lessons), and mapping studies of corticolimbic stimulation effects on arousal are reviving Heath-style affective cartography with modern methods (PMC).
Bottom line: Heath's specific protocols were never ethically replicated in humans; his disease theories failed; but his core phenomenology — euphoria, hypersexuality, compulsive self-administration from stimulation of septal/accumbens/MFB reward circuitry — has been repeatedly, often unintentionally, reproduced in modern psychiatric DBS, reinterpreted as "wanting" rather than pleasure, and now drives a reinvigorated clinical field that treats those very effects as safety signals to be avoided.
Happy to drill deeper into any strand — e.g., the MFB depression trials or the wanting/liking debate — if useful.
Oct 28, 9:16am
This is a shared conversation and may include unverified content that doesn't reflect Mistral AI's views. Login to resume chatting.
This is a shared conversation and may include unverified content that doesn't reflect Mistral AI's views. Login to resume chatting.